Plasma lipidomics reveal systemic changes persistent throughout early life following a childhood burn injury

Abstract

Background: Non-severe paediatric burns can result in poor long-term health outcomes. This occurs even in cases with good acute burn-related outcomes, including minimal scarring. The mechanisms that underpin the transition from non-severe burn to sustained negative long-term health impacts are currently unknown. However, sustained metabolic and immune changes have been observed in paediatric burn studies, suggesting these changes may be important. The plasma lipidome consists of a rich pool of bioactive metabolites that play critical roles in systemic processes including molecular signalling and inflammation. We hypothesised that changes in the plasma lipidome may reflect underlying changes in health status and be linked to long-term health after burn trauma. Methods: This study analysed the lipidome in children who had previously experienced a non-severe burn, compared to non-injured controls. Thirty-three participants were recruited between the ages of 5 and 8 years who had experienced a non-severe burn between the ages of 1 and 3 years. Plasma samples were also collected from a non-injured, healthy, age and gender matched control group (n = 21). Plasma lipids were measured using reversed-phase liquid chromatography-mass spectrometry (LC-MS). Results: In total 838 reproducible lipid species from 19 sub-classes passed quality control procedures and progressed to statistical analysis. Analysis of individual lipid metabolites showed significantly higher concentrations of lysophosphatidylethanolamines and phosphatidylethanolamines, and significantly lower concentrations in myristic, palmitic and palmitoleic acids in the plasma of those who had experienced burn injury compared to controls. Conclusion: Long-term changes in the lipid profile may give insight into the mechanisms underlying poor long-term health subsequent to non-severe burn injury. Further work to investigate the relationship between long-term pathology and lipidomic changes may lead to a better understanding of the causes of secondary morbidity post-burn and to clinical intervention to reduce the long-term health burden of burn trauma.

Keywords

Lipidomics / Lipids / Burns / Trauma / Paediatric / Children / Mass spectrometry

References

[1] Valvis SM, Waithman J, Wood FM, Fear MW, Fear VS. The immune response to skin trauma is dependent on the Etiology of injury in a mouse model of burn and excision. J Invest Dermatol. 2015; 135: 2119-28.

[2] Cassidy JT, Phillips M, Fatovich D, Duke J, Edgar D, Wood F. Developing a burn injury severity score (BISS): adding age and total body surface area burned to the injury severity score (ISS) improves mortality concordance. Burns. 2014; 40: 805-13.

[3] Fear VS, Poh W-P, Valvis S, Waithman JC, Foley B, Wood FM, et al. Timing of excision after a non-severe burn has a significant impact on the subsequent immune response in a murine model. Burns. 2016; 42: 815-24.

[4] Duke JM, Rea S, Boyd JH, Randall SM, Wood FM. Mortality after burn injury in children: a 33-year population-based study. Pediatrics. 2015; 135: e903-10. https://doi.org/10.1542/peds.2014-3140.

[5] Ryder C, Mackean T, Hunter K, Rogers K, Holland AJA, Ivers R. Burn injuries in hospitalized Australian children-an epidemiological profile. J Burn Care Res. 2021; 42: 381-9.

[6] Duke JM, Randall SM, Fear MW, Boyd JH, Rea S, Wood FM. Long-term effects of Pediatric burns on the circulatory system. Pediatrics. 2015; 136: e1323-30. https://doi.org/10.1542/peds.2015-1945.

[7] Duke JM, Randall SM, Fear MW, Boyd JH, Rea S, Wood FM. Increased admissions for musculoskeletal diseases after burns sustained during childhood and adolescence. Burns. 2015; 41: 1674-82.

[8] Duke JM, Randall SM, Fear MW, Boyd JH, O’Halloran E, Rea S, et al. Increased admissions for diabetes mellitus after burn. Burns. 2016; 42: 1734-9.

[9] Stevenson AW, Randall SM, Boyd JH, Wood FM, Fear MW, Duke JM. Burn leads to long-term elevated admissions to hospital for gastrointestinal disease in a west Australian population based study. Burns. 2017; 43: 665-73.

[10] Duke JM, Randall SM, Wood FM, Boyd JH, Fear MW.Burns and long-term infectious disease morbidity: a population-based study. Burns. 2017; 43: 273-81.

[11] Jeschke MG, Gauglitz GG, Kulp GA, Finnerty CC, Williams FN, Kraft R, et al. Long-term Persistance of the pathophysiologic response to severe burn injury. PLoS One. 2011; 6: e21245. https://doi.org/10.1371/journal.pone.0021245.

[12] Nielson CB, Duethman NC, Howard JM, Moncure M, Wood JG. Burns: pathophysiology of systemic complications and current management. J Burn Care Res. 2017; 38: e469-81. https://doi.org/10.1097/BCR.0000000000000355.

[13] Kuznetsova TA, Andryukov BG, Besednova NN. Modern aspects of burn injury Immunopathogenesis and prognostic Immunobiochemical markers (mini-review). BioTech (Basel). 2022; 11: 18. https://doi.org/10.3390/biotech11020018.

[14] Johnson BZ, McAlister S, McGuire HM, Palanivelu V, Stevenson A, Richmond P, et al. Pediatric burn survivors have long-term immune dysfunction with diminished vaccine response. Front Immunol. 2020; 11: 1481. doi.org/10.3389/fimmu.2020.01481.

[15] Begum S, Johnson BZ, Morillon A-C, Yang R, Bong SH, Whiley L, et al. Systemic long-term metabolic effects of acute non-severe paediatric burn injury. Sci Rep. 2022; 12: 13043-10. https://doi.org/10.1038/s41598-022-16886-w.

[16] Capolupo L, Khven I, Lederer AR, Mazzeo L, Glousker G, Ho S, et al. Sphingolipids control dermal fibroblast heterogeneity. Science. 2022; 376: eabh1623. https://doi.org/10.1126/science.abh1623.

[17] Meikle TG, Huynh K, Giles C, Meikle PJ. Clinical lipidomics: realizing the potential of lipid profiling. J Lipid Res. 2021; 62: 100127. https://doi.org/10.1016/j.jlr.2021.100127.

[18] Zhang C, Wang K, Yang L, Liu R, Chu Y, Qin X, et al. Lipid metabolism in inflammation-related diseases. Analyst. 2018; 143: 4526-36.

[19] Khubchandani A, Shaikh M, Sachde J, Suri M, Sanghani H, Gandhi P. Study of alterations in lipid profile after burn injury. Indian Journal of Burns. 2011; 19: 52-5.

[20] Arneth B, Arneth R, Shams M. Metabolomics of type 1 and type 2 diabetes. Int J Mol Sci. 2019; 20. https://doi.org/10.3390/ijms20102467.

[21] Tabassum R, Rämö JT, Ripatti P, Koskela JT, Kurki M, Karjalainen J, et al. Genetic architecture of human plasma lipidome and its link to cardiovascular disease. Nat Commun. 2019; 10: 4329. https://doi.org/10.1038/s41467-019-11954-8.

[22] Gray N, Lawler NG, Zeng AX, Ryan M, Bong SH, Boughton BA, et al. Diagnostic potential of the plasma Lipidome in infectious disease: application to acute SARS-CoV-2 infection. Meta. 2021; 11: 467. https://doi.org/10.3390/metabo11070467.

[23] Adams KJ, Pratt B, Bose N, Dubois LG, St John-Williams L, Perrott KM, et al. Skyline for small molecules: a unifying software package for quantitative metabolomics. J Proteome Res. 2020; 19: 1447-58.

[24] Luan H, Ji F, Chen Y, Cai Z. statTarget: a streamlined tool for signal drift correction and interpretations of quantitative mass spectrometry-based omics data. Anal Chim Acta. 2018; 1036: 66-72.

[25] Gaud C, Sousa BC, Nguyen A, Fedorova M, Ni Z, O’Donnell VB, et al. BioPAN: a web-based tool to explore mammalian lipidome metabolic pathways on LIPID MAPS. F1000Res. 2021; 10: 4. https://doi.org/10.12688/f1000research.28022.2.

[26] Chiurchiù V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. 2018; 9. https://doi.org/10.3389/fimmu.2018.00038.

[27] Freigang S. The regulation of inflammation by oxidized phospholipids. Eur J Immunol. 2016; 46: 1818-25.

[28] Miao H, Chen L, Hao L, Zhang X, Chen Y, Zhihua R, et al. Stearic acid induces proinflammatory cytokine production partly through activation of lactate-HIF1α pathway in chondrocytes. Sci Rep. 2015; 5. https://doi.org/10.1038/srep13092.

[29] Nambiar S, Tan DBA, Clynick B, Bong SH, Rawlinson C, Gummer J, et al. Untargeted metabolomics of human plasma reveal lipid markers unique to chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Proteomics Clin Appl. 2021; 15: e2000039. https://doi.org/10.1002/prca.202000039.

[30] Chamani S, Bianconi V, Tasbandi A, Pirro M, Barreto GE, Jamialahmadi T, et al. Resolution of inflammation in neurodegenerative diseases: the role of Resolvins. Mediat Inflamm. 2020; 2020: 3267172. https://doi.org/10.1155/2020/3267172.

[31] Korbecki J, Bajdak-Rusinek K. The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms. Inflamm Res. 2019; 68: 915-32.

[32] Akazawa Y, Morisaki T, Fukuda H, Norimatsu K, Shiota J, Hashiguchi K, et al. Significance of serum palmitoleic acid levels in inflammatory bowel disease. Sci Rep. 2021; 11: 16260. https://doi.org/10.1038/s41598-021-95923-6.

[33] Alonso-Castro A, Serrano Vega R, Gutiérrez S, Isiordia-Espinoza M, Solorio C. Myristic acid reduces skin inflammation and nociception. J Food Biochem. 2022; 46:e14013. https://doi.org/10.1111/jfbc.14013.

[34] Ohi K, Ursini G, Li M, Shin JH, Ye T, Chen Q, et al. DEGS2 polymorphism associated with cognition in schizophrenia is associated with gene expression in brain. Transl Psychiatry. 2015; 5: e550.

[35] Rozhkova AV, Zinovyeva MV, Sass AV, Zborovskaya IB, Limborska SA, Dergunova LV. Expression of sphingomyelin synthase 1 (SGMS1) gene varies in human lung and esophagus cancer. Mol Biol. 2014; 48: 340-6.

[36] Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014; 510: 58-67.

[37] Farina JA, Rosique MJ, Rosique RG. Curbing inflammation in burn patients. Int J Inflam. 2013; 2013: 715645. https://doi.org/10.1155/2013/715645.

[38] Zayed MA, Jin X, Yang C, Belaygorod L, Engel C, Desai K, et al. CEPT1-mediated Phospholipogenesis regulates endothelial cell function and ischemia-induced angiogenesis through PPARα. Diabetes. 2021; 70: 549-61.

[39] Schuiki I, Daum G. Phosphatidylserine decarboxylases, key enzymes of lipid metabolism. IUBMB Life. 2009; 61: 151-62.

[40] Nathan C, Ding A. Nonresolving inflammation. Cell. 2010; 140: 871-82.